Ignite Creation Date:
2025-12-24 @ 2:08 PM
Ignite Modification Date:
2026-02-26 @ 2:16 AM
Study NCT ID:
NCT06546995
Status:
COMPLETED
Last Update Posted:
2025-11-21
First Post:
2024-08-06
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000544', 'term': 'Alzheimer Disease'}], 'ancestors': [{'id': 'D003704', 'term': 'Dementia'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D024801', 'term': 'Tauopathies'}, {'id': 'D019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D019965', 'term': 'Neurocognitive Disorders'}, {'id': 'D001523', 'term': 'Mental Disorders'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 96}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2024-07-09', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-11', 'completionDateStruct': {'date': '2025-11-19', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-11-19', 'studyFirstSubmitDate': '2024-08-06', 'studyFirstSubmitQcDate': '2024-08-06', 'lastUpdatePostDateStruct': {'date': '2025-11-21', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2024-08-09', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-11-19', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Part A: Safety and Tolerability Assessments Based on Treatment Emergent Adverse Events (TEAEs) and Validated Clinical Scales', 'timeFrame': 'Up to 53 days', 'description': 'An AE is any untoward medical occurrence in a participant or clinical trial participant, temporally associated with the use of trial intervention, whether or not considered related to the trial intervention. Any AE occurring following the start of treatment or occurring before treatment but increasing in severity afterward were counted as treatment-emergent AE (TEAE). Clinically significant abnormalities in Clinical Laboratory Evaluations, ECGs, Vital Signs, Physical examinations, and Columbia Suicide Severity Rating Scale (C-SSRS) scores will be reported as TEAEs.'}, {'measure': 'Part B: Safety and Tolerability Assessments Based on Treatment Emergent Adverse Events and Validated Clinical Scales', 'timeFrame': 'Up to Week 10', 'description': 'An AE is any untoward medical occurrence in a participant or clinical trial participant, temporally associated with the use of trial intervention, whether or not considered related to the trial intervention. Any AE occurring following the start of treatment or occurring before treatment but increasing in severity afterward were counted as a TEAE. Clinically significant abnormalities in Clinical Laboratory Evaluations, ECGs, Vital Signs, Physical examinations, and C-SSRS scores will be reported as TEAEs.'}, {'measure': 'Part B: Change from Baseline to Week 8 on the Cohen-Mansfield Agitation Inventory (CMAI) Total Score', 'timeFrame': 'Baseline to Week 8', 'description': 'The CMAI is a 29-item scale to assess the frequency of agitated behaviors. The 29 agitated behaviors are categorized into agitation factors, including aggressive behavior, physically non-aggressive behavior, and verbally agitated behavior. Each item is rated over the past 2 weeks on a 7-point scale ranging from "Never" (score of 1) to "Several times per hour" (score of 7). The CMAI total score is calculated as the sum of all 29 items and range from 29 (no agitation) to 203 (most severe agitation). A score \\>45 is commonly regarded as clinically significant agitation.'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ["Alzheimer's Disease", 'Agitation Associated Dementia', 'NMRA-323511'], 'conditions': ["Alzheimer's Disease", 'Healthy Elderly']}, 'descriptionModule': {'briefSummary': "This study consists of 2 parts, Part A and Part B. Part A is a single center, randomized, double-blind, placebo-controlled cohort designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of NMRA-323511 among healthy elderly.\n\nPart B is a multicenter, randomized, double-blinded, placebo-controlled, parallel-group cohort to evaluate the safety, tolerability, and efficacy of NMRA-323511 among adults with Agitation Associated with Dementia due to Alzheimer's Disease.\n\nPart A consists of a Screening Period (up to 28 days), a 10-day Treatment Period, and a 10- day Follow-up clinic visit after last dose of study treatment.\n\nPart B consists of a Screening Period (up to 28 days), an 8-week Treatment Period, and a 10-day Follow-up clinic visit after last dose of study treatment."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '90 Years', 'minimumAge': '55 Years', 'healthyVolunteers': True, 'eligibilityCriteria': "Inclusion Criteria:\n\nPart A\n\n* Healthy participants\n* Age 65 to 80 years\n* Body mass index (BMI) ≥18.0 and ≤32.0 kg/m\\^2 at the screening and check-in visit\n\nPart B\n\n* Participants aged 55 to 90 years\n* Diagnosis of probable AD or Alzheimer's clinical syndrome according to the National Institute of Aging-Alzheimer's Association criteria at least 12 months prior to screening\n* Agitation meets the International Psychogeriatric Association (IPA) consensus definition\n* Mini-Mental State Examination (MMSE) score = 5 - 24 (mild to severe dementia) at screening\n\nExclusion Criteria:\n\nPart A\n\n* Participant is actively suicidal\n* Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit\n* Diagnosis of epilepsy taking anticonvulsants for seizure control, history of seizures\n\nPart B\n\n* Dementia or memory impairment due to a reason other than AD\n* Clinically significant neurologic disorder other than AD\n* Have any clinically significant and uncontrolled medical condition\n\nNote: Other protocol defined inclusion/exclusion criteria may apply"}, 'identificationModule': {'nctId': 'NCT06546995', 'briefTitle': "Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease", 'organization': {'class': 'INDUSTRY', 'fullName': 'Neumora Therapeutics, Inc.'}, 'officialTitle': "A Phase 1b, Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease", 'orgStudyIdInfo': {'id': 'NMRA-323511-104'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Part A: NMRA-323511', 'interventionNames': ['Drug: NMRA-323511']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Part A: Placebo', 'interventionNames': ['Drug: Placebo']}, {'type': 'EXPERIMENTAL', 'label': 'Part B: NMRA-323511', 'interventionNames': ['Drug: NMRA-323511']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Part B: Placebo', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'name': 'NMRA-323511', 'type': 'DRUG', 'description': 'Participants will receive NMRA-323511 orally.', 'armGroupLabels': ['Part A: NMRA-323511', 'Part B: NMRA-323511']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'Participants will receive matching placebo tablets orally.', 'armGroupLabels': ['Part A: Placebo', 'Part B: Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '85286', 'city': 'Chandler', 'state': 'Arizona', 'country': 'United States', 'facility': 'Neumora Investigator Site', 'geoPoint': {'lat': 33.30616, 'lon': -111.84125}}, {'zip': '85283', 'city': 'Tempe', 'state': 'Arizona', 'country': 'United States', 'facility': 'Neumora Investigator Site', 'geoPoint': {'lat': 33.41477, 'lon': -111.90931}}, {'zip': '92626', 'city': 'Costa Mesa', 'state': 'California', 'country': 'United States', 'facility': 'Neumora Investigator Site', 'geoPoint': {'lat': 33.64113, 'lon': -117.91867}}, {'zip': '90717', 'city': 'Lomita', 'state': 'California', 'country': 'United States', 'facility': 'Neumora Investigator Site', 'geoPoint': {'lat': 33.79224, 'lon': -118.31507}}, {'zip': '94596', 'city': 'Walnut Creek', 'state': 'California', 'country': 'United States', 'facility': 'Neumora Investigator Site', 'geoPoint': {'lat': 37.90631, 'lon': -122.06496}}, {'zip': '34205', 'city': 'Bradenton', 'state': 'Florida', 'country': 'United States', 'facility': 'Neumora Investigator Site', 'geoPoint': {'lat': 27.49893, 'lon': -82.57482}}, {'zip': '33467', 'city': 'Greenacres City', 'state': 'Florida', 'country': 'United States', 'facility': 'Neumora Investigator Site', 'geoPoint': {'lat': 26.62368, 'lon': -80.12532}}, {'zip': '33009', 'city': 'Hallandale', 'state': 'Florida', 'country': 'United States', 'facility': 'Neumora Investigator Site', 'geoPoint': {'lat': 25.9812, 'lon': -80.14838}}, {'zip': '33016', 'city': 'Hialeah', 'state': 'Florida', 'country': 'United States', 'facility': 'Neumora Investigator Site', 'geoPoint': {'lat': 25.8576, 'lon': -80.27811}}, {'zip': '33126', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'Neumora Investigator Site', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33137', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'Neumora Investigator Site', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33155', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'Neumora Investigator Site', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33166', 'city': 'Miami Springs', 'state': 'Florida', 'country': 'United States', 'facility': 'Neumora Investigator Site', 'geoPoint': {'lat': 25.82232, 'lon': -80.2895}}, {'zip': '32807', 'city': 'Orlando', 'state': 'Florida', 'country': 'United States', 'facility': 'Neumora Investigator Site', 'geoPoint': {'lat': 28.53834, 'lon': -81.37924}}, {'zip': '33024', 'city': 'Pembroke Pines', 'state': 'Florida', 'country': 'United States', 'facility': 'Neumora Investigator Site', 'geoPoint': {'lat': 26.00315, 'lon': -80.22394}}, {'zip': '32127', 'city': 'Port Orange', 'state': 'Florida', 'country': 'United States', 'facility': 'Neumora Investigator Site', 'geoPoint': {'lat': 29.13832, 'lon': -80.99561}}, {'zip': '30318', 'city': 'Atlanta', 'state': 'Georgia', 'country': 'United States', 'facility': 'Neumora Investigator Site', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'zip': '96817', 'city': 'Honolulu', 'state': 'Hawaii', 'country': 'United States', 'facility': 'Neumora Investigator Site', 'geoPoint': {'lat': 21.30694, 'lon': -157.85833}}, {'zip': '83704', 'city': 'Boise', 'state': 'Idaho', 'country': 'United States', 'facility': 'Neumora Investigator Site', 'geoPoint': {'lat': 43.6135, 'lon': -116.20345}}, {'zip': '02478', 'city': 'Belmont', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Neumora Investigator Site', 'geoPoint': {'lat': 42.39593, 'lon': -71.17867}}, {'zip': '48085', 'city': 'Troy', 'state': 'Michigan', 'country': 'United States', 'facility': 'Neumora Investigator Site', 'geoPoint': {'lat': 42.60559, 'lon': -83.14993}}, {'zip': '08755', 'city': 'Toms River', 'state': 'New Jersey', 'country': 'United States', 'facility': 'Neumora Investigator Site', 'geoPoint': {'lat': 39.95373, 'lon': -74.19792}}, {'zip': '11229', 'city': 'Brooklyn', 'state': 'New York', 'country': 'United States', 'facility': 'Neumora Investigator Site', 'geoPoint': {'lat': 40.6501, 'lon': -73.94958}}, {'zip': '13057', 'city': 'East Syracuse', 'state': 'New York', 'country': 'United States', 'facility': 'Neumora Investigator Site', 'geoPoint': {'lat': 43.06534, 'lon': -76.07853}}, {'zip': '28204', 'city': 'Charlotte', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Neumora Investigator Site', 'geoPoint': {'lat': 35.22709, 'lon': -80.84313}}, {'zip': '75149', 'city': 'Mesquite', 'state': 'Texas', 'country': 'United States', 'facility': 'Neumora Investigator Site', 'geoPoint': {'lat': 32.7668, 'lon': -96.59916}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Neumora Therapeutics, Inc.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}